Study | Country Study period Study design |
Data source | Exposure definition | Non-exposure definition | Exposition period | Sample size (exposed/unexposed) Or (case / control) |
Remarks | Risk of bias |
---|---|---|---|---|---|---|---|---|
Ishikawa (Controls unexposed, disease free) 2023 |
Japan 2010 - 2019 retrospective cohort (claims database) |
A large administrative claims database from JMDC Inc. (Tokyo, Japan), which contained all the inpatient, outpatient, and pharmacy claims received from insurers. | Pregnant women with chronic hypertension and prescribed Amlodipine in the first trimester. |
unexposed, disease free
Pregnant women without hypertensive disorders in the first trimester. |
1st trimester | 44 / 74213 | ||
A large administrative claims database from JMDC Inc. (Tokyo, Japan), which contained all the inpatient, outpatient, and pharmacy claims received from insurers. These claims include prescribed medications. | ||||||||
Ishikawa (Controls unexposed, sick) 2023 |
Japan 2010 - 2019 retrospective cohort (claims database) |
A large administrative claims database from JMDC Inc. (Tokyo, Japan), which contained all the inpatient, outpatient, and pharmacy claims received from insurers. | Pregnant women with chronic hypertension and prescribed Amlodipine in the first trimester. |
unexposed, sick
Pregnant women chronic hypertension but no first-trimester antihypertensive prescriptions. |
1st trimester | 44 / 1007 | ||
A large administrative claims database from JMDC Inc. (Tokyo, Japan), which contained all the inpatient, outpatient, and pharmacy claims received from insurers. These claims include prescribed medications. | ||||||||
Mito 2019 |
Japan 2008 - 2016 retrospective cohort |
National Center for Child Health and Development (NCCHD, Tokyo), Osaka Women’s and Children’s Hospital (OWCH, Osaka), and National Cerebral and Cardiovascular Center (NCCC, Osaka), Japan. | Chronic hypertensive pregnant women who received Amlodipine, a calcium channel blocker during the first trimester (from estimated conception to 11 weeks and 6 days’ gestation). |
unexposed, sick
Chronic hypertensive pregnant women who did not receive any antihypertensive drugs. |
at least 1st trimester | 48 / 129 | Data versus Group O (pregnancies exposed to antihypertensives other than amlodipine (including other calcium channel blockers)) cannot be used, because calcium channel blockers in both groups. | |
Data extracted from mothers’ electronic health records. | ||||||||
Weber-Schoendorfer 2008 |
Finland, France, Germany, Israel, Italy, the Netherlands. 1986 - 2003 prospective cohort |
A multicenter (n = 11), prospective observational study of the European Network of Teratology Information Services (ENTIS). | Pregnant women with first- trimester exposure to Amlodipine. |
unexposed (general population or NOS)
Pregnant women who had been counseled during pregnancy about exposures known to be non-teratogenic. |
at least 1st trimester | 38 / 806 | ||
A similarly structured questionnaire was used by all the centres to record the following data at the first contact during (early) pregnancy before the pregnancy outcome was known, including details of drug exposure (timing in pregnancy, dose, and duration). |
Study | Country Study period Study design |
Data source | Case | Control | Exposition | Exposition period | Sample size (exposed/unexposed) Or (case / control) |
Remarks | Risk of bias |
---|
Risk of bias: : NA; : low; : moderate; : serious; : critical; : unclear;